Claims

[Claim 1]

A method for analyzing a biological sample obtained from a subject, comprising:

analyzing components contained in a biological sample by an assay using a first molecule selected from a group consisting of a molecule binding to SerpinA3, and a molecule binding to Gal3BP, and a second molecule that is BC2LCN.

[Claim 2]

The method according to claim 1,

wherein the first molecule is an antibody binding to SerpinA3.

[Claim 3]

The method according to claim 1,

wherein the first molecule is an antibody binding to Gal3BP.

[Claim 4]

The method according to any one of claims 1 to 3,

wherein the subject has a cancer or has a potential to have the cancer.

[Claim 5]

The method according to claim 4,

wherein the subject has a pancreatic cancer or has a potential to have the pancreatic cancer.

[Claim 6]

The method according to claim 5,

wherein the subject has a stage I or II pancreatic cancer or has a potential to have the stage I or II pancreatic cancer.

[Claim 7]

A kit for a sandwich assay, a kit for an immunochromatographic assay, a kit for lectin electrophoresis, a kit for mass spectrometry, a kit for lectin affinity chromatography, or a kit for μTAS, comprising:

a first molecule selected from a group consisting of a molecule binding to SerpinA3, and a molecule binding to Gal3BP; and

a second molecule that is BC2LCN, wherein the kit is capable of being used to measure an amount of a glycoprotein in a biological sample of a subject, using the first molecule and the second molecule.

[Claim 8]

The kit according to claim 7,

wherein the first molecule is an antibody binding to SerpinA3 and a protein portion of the glycoprotein is SerpinA3.

[Claim 9]

The kit according to claim 7,

wherein the first molecule is an antibody binding to Gal3BP and a protein portion of the glycoprotein is Gal3BP.

[Claim 10]

The kit according to claim 7, comprising:

a second molecule that is immobilized BC2LCN; and

a first labeled molecule selected from a group consisting of a labeled antibody binding to SerpinA3, and a labeled antibody binding to Gal3BP.

[Claim 11]

The kit according to any one of claims 7 to 10,

wherein the kit is used for detecting a cancer.

[Claim 12]

The kit according to claim 11, wherein the cancer is a pancreatic cancer.

[Claim 13]

The kit according to claim 12,

wherein the cancer is a stage I or II pancreatic cancer.